[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617017":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":41,"collaborators":39,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":39,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":39,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":69,"whyStopped":39,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":39},{"fullName":5,"class":6},"Qilu Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"QLS7305","EXPERIMENTAL","QLS7305 Injection",[13],"Drug: QLS7305 Injection",{"label":15,"type":16,"description":15,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo Control",[20,24],{"type":21,"name":11,"description":11,"armGroupLabels":22,"otherNames":23},"DRUG",[9],[9],{"type":21,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Placebo Control","The placebo is a sterile solution that matches the appearance, volume, and packaging of the QLS7305 injection. It contains no active pharmaceutical ingredient and is administered subcutaneously following the same dosing schedule as the active comparator (single or multiple doses).",[15],[15],[30],{"name":31,"affiliation":32,"role":33},"Zhang Jing, Professor","Huashan Hospital","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Wu Cuiyun, Professor","CONTACT","021-5288 8921",null,"wucuiyun@fudan.edu.cn",{"type":42,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100617017","phase-1-a-phase-i-trial-of-subcutaneous-qls7305-in-healthy-adults-100617017",false,"NCT07313150","A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of QLS7305 Following Subcutaneous Administration in Healthy Chinese Participants.","Inclusion Criteria:\n\nAged between 18 and 55 years (inclusive) Physical examination, vital signs, laboratory tests, 12-lead ECG, and imaging findings are within normal ranges.\n\nBody weight ≥50 kg for males and ≥45 kg for females, with a BM) between 18.0 and 28 kg\u002Fm² (inclusive).\n\nWilling or has complied with the administration of meningococcal and pneumococcal vaccines as required by the protocol.\n\nNo plan to donate sperm or ova, no pregnancy plan, and voluntarily agrees to use effective contraception methods from the signing of the ICF until 12 months after administration of the investigational product.\n\nAble to understand and comply with the study procedures, voluntarily participate in the trial, and provide written informed consent.\n\nExclusion Criteria:\n\nHistory of food or drug allergy, and\u002For known allergy to GalNAc. History of definite infection with encapsulated bacteria within 6 months prior to screening.\n\nHistory of recurrent or chronic infection within 3 months prior to screening. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection within 1 month prior to baseline.\n\nAny disease at screening that, in the investigator's judgment, could affect the study data.\n\nHistory of malignancy. Any condition that may affect drug absorption. History of splenectomy or congenital asplenia. History of congenital or acquired complement deficiency or disorder. History of allergic diseases (e.g., allergic asthma, allergic rhinitis).",true,"ALL","18 Years","55 Years",{"count":55,"type":56},60,"ESTIMATED","INTERVENTIONAL",[59],"PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary characteristics of the investigational drug QLS7305 in healthy adult participants in China. The main questions it aims to answer are:\n\nWhat is the safety and tolerability profile of single and multiple subcutaneous doses of QLS7305 in healthy adults? What are the pharmacokinetic (PK) characteristics of QLS7305 and its major metabolites? What are the pharmacodynamic (PD) effects of QLS7305 on the complement system (e.g., serum C3 levels and complement activity)? Does QLS7305 induce an immunogenic response (anti-drug antibodies)? What is the effect of QLS7305 on the QTc interval? Investigators will compare different dose levels of QLS7305 to a placebo group to see the effects on safety, tolerability, and the measured parameters.\n\nParticipants will:\n\nBe enrolled in one of two parts of the study:\n\nPart A (Single Ascending Dose): Receive a single dose of QLS7305 or placebo. Part B (Multiple Ascending Dose): Receive multiple doses of QLS7305 or placebo (doses selected based on Part A results).\n\nReceive prophylactic antibiotics (Penicillin V) after the first dose until their serum complement C3 level recovers, as a safety precaution.\n\nUndergo close safety monitoring throughout the study, including a follow-up period of up to 337 days to ensure safety parameters return to acceptable levels.",[62],"Healthy Volunteers - Male and Female",[9,64,65,66,67,68],"Double-stranded small interfering ribonucleic acid (siRNA) targeting complement","First-in-human","C3","SAD","MAD","NOT_YET_RECRUITING","2025-12-22",{"date":72,"type":73},"2025-12-31","ACTUAL",{"date":75,"type":56},"2026-01",{"date":77,"type":56},"2027-12",{"name":5,"class":6}]